Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment

Background: Parkinson's disease (PD) is a neurodegenerative disorder that often requires long-term management of motor symptoms. Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) has shown promising results in al-leviating motor fluctuations and improving quality of life. This study aimed to evaluate the efficacy and safe-ty of transgastric jejunostomy (PEG-J) as a delivery method for LCIG in a cohort of 43 PD patients. Material/Methods: Forty-three PD patients who were candidates for LCIG therapy underwent transgastric jejunostomy to facili-tate continuous infusion of LCIG. The primary outcomes assessed were motor symptom improvement, reduc-tion in motor fluctuations, and medication-related adverse events. Secondary outcomes included changes in quality of life, dyskinesia severity, and healthcare resource utilization. Results: The results of this study demonstrated significant improvements in motor symptoms, reduction in motor fluc-tuations, and enhanced quality of life following PEG-J for LCIG infusion. The treatment was generally well-tol-erated, with a low incidence of procedure-related complications. Notably, the use of PEG-J allowed for precise and continuous delivery of LCIG, minimizing variations in drug absorption and ensuring consistent therapeutic levels. Conclusions: Transgastric jejunostomy (PEG-J) offers an effective approach for the continuous infusion of LCIG in Parkinson's disease treatment. This method provides a stable and reliable delivery system, leading to improved symptom control and enhanced quality of life for PD patients.